Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AUP Aurinia Pharmaceuticals		C$0.00	C$11.77 ▼ C$26.00	C$2.15B	N/A	229,895 shs	4.61 million shs
BHC Bausch Health Cos	$7.80 -2.8%	$6.44	$4.25 ▼ $9.85	$2.89B	0.41	2.71 million shs	2.81 million shs
CARA Cara Therapeutics		$15.19	$8.13 ▼ $19.08	$24.33M	0.41	22,224 shs	237,144 shs
TLRY Tilray Brands	$1.06 -7.0%	$0.61	$0.35 ▼ $1.95	$1.17B	1.85	40.75 million shs	42.33 million shs

7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AUP Aurinia Pharmaceuticals	0.00%	0.00%	0.00%	0.00%	0.00%
BHC Bausch Health Cos	-3.84%	+20.13%	+27.10%	+71.73%	+39.97%
CARA Cara Therapeutics	0.00%	0.00%	0.00%	0.00%	+32.42%
TLRY Tilray Brands	+10.68%	+24.05%	+83.49%	+151.71%	-41.24%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AUP Aurinia Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
BHC Bausch Health Cos	4.3088 of 5 stars	2.0	4.0	0.0	4.0	3.9	3.3	1.3
CARA Cara Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
TLRY Tilray Brands	2.5752 of 5 stars	3.1	1.0	0.0	0.0	3.8	1.7	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AUP Aurinia Pharmaceuticals	0.00	N/A	N/A	N/A
BHC Bausch Health Cos	2.00	Hold	$9.00	16.50% Upside
CARA Cara Therapeutics	0.00	N/A	N/A	N/A
TLRY Tilray Brands	2.20	Hold	$1.92	81.67% Upside

Current Analyst Ratings Breakdown

Latest TLRY, AUP, BHC, and CARA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target	Details
7/29/2025	TLRY Tilray Brands	Zelman & Associates Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral

(Data available from 8/19/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AUP Aurinia Pharmaceuticals	C$57.59M	0.00	N/A	6.75	C$2.59 per share	0.00
BHC Bausch Health Cos	$9.86B	0.29	$7.15 per share	1.08	($0.89) per share	-8.68
CARA Cara Therapeutics	$7.14M	0.00	N/A	N/A	$12.58 per share	0.00
TLRY Tilray Brands	$210.48M	5.52	$0.15 per share	7.13	$1.40 per share	0.75

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AUP Aurinia Pharmaceuticals	N/A	-C$1.48	N/A	N/A	N/A	N/A	N/A	N/A	N/A
BHC Bausch Health Cos	-$46M	$0.26	29.75	1.66	N/A	0.99%	-852.36%	5.25%	10/29/2025 (Estimated)
CARA Cara Therapeutics	-$118.51M	-$21.01	N/A	N/A	N/A	-1,099.76%	-367.97%	-107.43%	N/A
TLRY Tilray Brands	-$2.19B	-$2.31	N/A	N/A	N/A	-265.69%	-6.83%	-5.45%	10/9/2025 (Estimated)

Latest TLRY, AUP, BHC, and CARA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
7/30/2025	Q2 2025	BHC Bausch Health Cos	$0.97	$0.90	-$0.07	$0.40	$2.47 billion	$2.57 billion
7/28/2025	Q4 2025	TLRY Tilray Brands	-$0.03	$0.02	+$0.05	-$1.30	$250.41 million	$224.54 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AUP Aurinia Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
BHC Bausch Health Cos	N/A	N/A	N/A	N/A	N/A
CARA Cara Therapeutics	N/A	N/A	N/A	N/A	N/A
TLRY Tilray Brands	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AUP Aurinia Pharmaceuticals	2.69	11.93	11.02
BHC Bausch Health Cos	141.90	1.31	0.98
CARA Cara Therapeutics	N/A	4.77	4.71
TLRY Tilray Brands	0.20	2.46	1.49

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AUP Aurinia Pharmaceuticals	N/A
BHC Bausch Health Cos	78.65%
CARA Cara Therapeutics	44.66%
TLRY Tilray Brands	9.35%

Insider Ownership

Company	Insider Ownership
AUP Aurinia Pharmaceuticals	N/A
BHC Bausch Health Cos	8.05%
CARA Cara Therapeutics	3.10%
TLRY Tilray Brands	0.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AUP Aurinia Pharmaceuticals	300	128.40 million	N/A	Not Optionable
BHC Bausch Health Cos	20,700	370.13 million	340.07 million	Optionable
CARA Cara Therapeutics	80	4.57 million	4.43 million	Optionable
TLRY Tilray Brands	2,842	1.10 billion	1.09 billion	Optionable

TLRY, BHC, AUP, and CARA Headlines

Recent News About These Companies

Tilray Brands (NASDAQ:TLRY) Shares Up 9.2% - Time to Buy?

4 hours ago | marketbeat.com

Promising Cannabis Stocks To Add to Your Watchlist - August 18th

5 hours ago | marketbeat.com

Tilray Brands (NASDAQ:TLRY) Shares Gap Up - Here's Why

August 19 at 12:47 PM | marketbeat.com

Tilray Brands (NASDAQ TLRY) Rises Amid NASDAQ Composite Market Trends

August 19 at 8:07 AM | kalkinemedia.comK

Promising Cannabis Stocks To Add to Your Watchlist - August 17th

August 18 at 1:51 PM | marketbeat.com

National Bank of Canada FI Sells 763,247 Shares of Tilray Brands, Inc. $TLRY

August 18 at 4:15 AM | marketbeat.com

Tilray Brands (TLRY) Boosts Revenue Mix with New Cannabis, Wellness, and Beverage Products

August 17 at 8:17 PM | insidermonkey.com

Cannabis Stocks Worth Watching - August 16th

August 17 at 1:44 PM | marketbeat.com

Best Canadian Cannabis Stocks in 2025

August 17 at 10:00 AM | marijuanastocks.comM

Tilray Brands (NASDAQ:TLRY) Trading Down 7.2% - Here's What Happened

August 16 at 2:11 PM | marketbeat.com

Best Cannabis Stocks To Follow Today - August 15th

August 16 at 12:32 PM | marketbeat.com

Tilray Brands, Inc. (TLRY) Declines More Than Market: Some Information for Investors

August 15, 2025 | zacks.com

Cannabis Stocks Worth Watching - August 14th

August 15, 2025 | marketbeat.com

Tilray Brands (NASDAQ:TLRY) Stock Price Down 4.4% - What's Next?

August 15, 2025 | marketbeat.com

Tilray Shares Drop After Seeking Extension to Meet Nasdaq Listing Requirements

August 14, 2025 | msn.com

Tilray Eyes Reverse Stock Split As Nasdaq Listing Compliance Pressure Mounts

August 14, 2025 | finance.yahoo.com

Tilray Brands: Improving Fundamentals, De-Risked Balance Sheet, And A Re-Igniting Narrative

August 14, 2025 | seekingalpha.com

Tilray Brands (NASDAQ:TLRY) Shares Gap Down - Time to Sell?

August 14, 2025 | marketbeat.com

Tilray Brands Reconfirms Strategy to Regain Nasdaq Compliance; Requests Extension to Meet Listing Requirements

August 14, 2025 | globenewswire.com

Tilray Brands (NASDAQ:TLRY) Shares Up 17.3% - Here's Why

August 13, 2025 | marketbeat.com

Promising Cannabis Stocks To Add to Your Watchlist - August 13th

August 13, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

TLRY, BHC, AUP, and CARA Company Descriptions

Aurinia Pharmaceuticals TSE:AUP

Aurinia Pharmaceuticals Inc., a biopharmaceutical company, develops and commercializes therapies to treat various diseases with unmet medical need in Japan and China. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company is headquartered in Victoria, Canada.

Bausch Health Cos NYSE:BHC

$7.80 -0.23 (-2.81%)

Closing price 03:59 PM Eastern

Extended Trading

$7.85 +0.05 (+0.71%)

As of 07:03 PM Eastern

Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health. The company operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The Salix segment provides gastroenterology products in the United States. The International segment sells aesthetic medical devices, branded pharmaceuticals, generic pharmaceuticals, and OTC products internationally. The Solta Medical segment engages in the sale of aesthetic medical devices. The Diversified segment offers pharmaceutical products in the areas of neurology and certain other therapeutic classes; generic products; ortho dermatologic; and dentistry products in the United States. The Bausch + Lomb segment offers products in the areas of vision care, surgical, and ophthalmic pharmaceuticals products. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.

Cara Therapeutics NASDAQ:CARA

Cara Therapeutics, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of chronic pruritus in the United States. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. It also develops Oral difelikefalin, which is in Phase II/III clinical trial to treat chronic pruritus with notalgia paresthetica. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; Vifor Fresenius Medical Care Renal Pharma Ltd. development and commercialization of KORSUVA injection for the treatment of moderate-to-severe pruritus in adult patients undergoing hemodialysis; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. Cara Therapeutics, Inc. was incorporated in 2004 and is based in Stamford, Connecticut.

Tilray Brands NASDAQ:TLRY

$1.06 -0.08 (-7.02%)

Closing price 04:00 PM Eastern

Extended Trading

$1.06 -0.01 (-0.47%)

As of 07:03 PM Eastern

Tilray, Inc. engages in the research, cultivation, processing, and distribution of medical cannabis. The company offers its products in Argentina, Australia, Canada, Chile, Croatia, Cyprus, the Czech Republic, Germany, New Zealand, and South Africa. Tilray, Inc. is headquartered in Canada.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time